diabetic nephropathy
Conditions
Interventions
spironolactone 12.5mg once a day for 24 weeks.
control
Sponsors
Diabetes, Endocrinology and Metabolism, Shinshu University Hospital
Takeda Clinic of Internal Medicine Miyamoto Clinic of Internal Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.patients with daiabetes who were 20year old or older 2.outpatients with diabetic nephropathy and albuminuria(more than 30 mg/g Cr) 3.eGFR more than 30mL/min/1.73m2 4.patients treated with RAS(renin-angiotensin system)blockade for more than 180 days 5.patients who were obtained written informed consent by free will after enough explanation.
Exclusion criteria
Exclusion criteria: 1.eGFR less than 30mL/min/1.73m2 2.patients with potassium more than 5.0mEq/l 3.patients who have already treated with spironolactone 4.patients who have an allergy career to a study drug 5.pregnant woman and the woman whom I am nursing 6.other conditions that are considered inappropriate to participate by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| reduction in the rate of albuminuria at 24 weeks after administration. | — |
Countries
Japan
Contacts
Public ContactAko Oiwa
Shinshu University Hospital Diabetes, Endocrinology and Metabolism
Outcome results
None listed